303 related articles for article (PubMed ID: 24788571)
1. Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.
Saglietti G; Placentino G; Schellino A
Clin Drug Investig; 2014 Jul; 34(7):513-9. PubMed ID: 24788571
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
4. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
Kostev K; Schokker E; Jacob L
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
[TBL] [Abstract][Full Text] [Related]
5. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
Bosi E; Dotta F; Jia Y; Goodman M
Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
[TBL] [Abstract][Full Text] [Related]
8. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch C
Vasc Health Risk Manag; 2008; 4(4):753-68. PubMed ID: 19065993
[TBL] [Abstract][Full Text] [Related]
10. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients.
Esposito K; Chiodini P; Maiorino MI; Capuano A; Cozzolino D; Petrizzo M; Bellastella G; Giugliano D
BMJ Open; 2015 Feb; 5(2):e005892. PubMed ID: 25687897
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses.
Mohanty IR; Borde M; Kumar C S; Maheshwari U
Phytomedicine; 2019 Apr; 57():158-165. PubMed ID: 30668318
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of DPP4i as the Fourth Drug in the Management of Type2 Diabetes Mellitus in Asian Indians Poorly Controlled by Use of at least 3 Oral Antidiabetic Drugs.
Panikar V; Joshi S; Tiwaskar M; Vadgama J; Nasikkar N; Kamat T; Deogaonkar N; Walawalkar S; Sachdev I; Jain C; Modh K; Panikar K; Kulkarni P; Medidar R
J Assoc Physicians India; 2019 Aug; 67(8):60-62. PubMed ID: 31562719
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 inhibitor treatment: β-cell response but not HbA
Kozlovski P; Bhosekar V; Foley JE
Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
19. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
20. DPP-4 inhibitors: what may be the clinical differentiators?
Gerich J
Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
